Plasma Fractionation Industry Growth, Development and Forecast Report 2030

Posted by Aryan on November 21st, 2023

The plasma fractionation market will observe a rate of 7.4% by the end of this decade, to reach USD 50,638 million by 2030.

The industry growth has a lot to do with the fast increase in the elderly population, susceptible to various rare disorders creating the requirement for plasma derivatives for treatment.

Furthermore, the industry is expanding because of the growing use of immunoglobulins in numerous therapeutic areas, increasing incidence of breathing problems, and mounting network of facilities of plasma collection.

The surge in the geriatric population all over the world is also a key factor accountable for the growing incidence of numerous uncommon disorders that require the usage of blood derivatives. With the count of people aged 65 and above will cross 1.5 billion by 2050, the use of the plasma fractionation method for deriving Ig and other therapeutic agents from the blood will increase.

On the basis of the product type, the immunoglobulins category will grow significantly at a rate of 7.9%, in the years to come. This is because of the wider commercial obtainability of plasma-derived immunoglobulins as opposed to other products and their growing use, particularly for treating patients with chronic inflammatory demyelinating polyneuropathy or inherent immune deficits.

Furthermore, the increasing occurrence of immunological and neurological diseases and growing off-label indications for IVIg, since it offers relief to patients with systemic lupus erythematosus and advances the cardiac consequences in babies borne by females with antiphospholipid syndrome throughout pregnancy, are powering the sales of the products.

Download free sample copy of this report: https://www.psmarketresearch.com/market-analysis/plasma-fractionation-market/report-sample

The neurology category dominated the industry, of about 28%, in 2022, because of the extensive usage of plasma-derived products for treating neurological ailments, which are increasing in incidence.

The oncology category will grow the fastest in the future, because the acceptance of cancer plasma treatments is rapidly increasing for addressing hard targets that were previously intractable, for example those with the probability for metastasis and resistance to drugs.

Moreover, a detailed examination of the intricate effects of cold atmospheric plasma in the treatment of cancer is essential to move on the road to its extensive clinical acceptance, which supports the expansion of the category.

North America led the share of plasma fractionation market, of about 55%, in 2022. This is because of the continuing expansion in the pharma research and development sector, increasing populace of patients suffering from hemophilia, increasing count of plasma collection centers, increasing paid plasma donation actions, and increasing portfolios of the products and presence of key players in the region.

It is because of the increasing elderly population all over the world, the requirement for plasma fractionation is on the rise in the years to come.